XR11576, a novel
phenazine, was developed as an inhibitor of both
topoisomerase I and II. This study characterized the ability of
XR11576 to inhibit both
enzymes, and determined its in vitro and in vivo antitumor efficacy against a number of murine and human
tumor models.
XR11576 was a potent inhibitor of purified
topoisomerase I and IIalpha, and exhibited similar potency for both
enzymes. The compound stabilized
enzyme-
DNA cleavable complexes indicating that it acted as a topoisomerase
poison. The DNA cleavage patterns obtained with
XR11576 were different from those induced by
camptothecin and
etoposide, which are
topoisomerase I and II
poisons, respectively.
XR11576 demonstrated potent cytotoxic activity against a variety of human and murine tumor cell lines (IC50=6-47 nM). Its activity profile was comparable to or better than that of many widely used anticancer drugs. Moreover,
XR11576 was unaffected by multidrug resistance (MDR) mediated by overexpression of either
P-glycoprotein or MDR-associated
protein, or by down-regulation of
topoisomerase II. The latter property supports the dual inhibitory mechanism of action of the compound.
XR11576 exhibited a similar pharmacokinetic profile in mice and rats after either i.v. or p.o. administration. In vivo
XR11576 showed marked efficacy against a number of
tumors including sensitive (H69/P) and multidrug-resistant (H69/LX4)
small cell lung cancer and the relatively refractory MC26 and HT29 colon
carcinomas following i.v. and p.o. administration. The efficacy of
XR11576 was at least comparable to that of
TAS-103, originally proposed as a dual inhibitor of
topoisomerase I and II. These results suggest that
XR11576 is a promising new
antitumor agent with oral and i.v. activity, and warrants further development.